Verge Healthtech Fund leads Lifeyears' €2.8M funding round
Lifeyear, a UK-Estonian health tech startup, has raised €2.8 million to launch its remote patient management platform, delivering at-home digital cardiovascular care. The round includes €1.5 million in deep tech grant funding from the Estonian government, as well as €1.3 million from venture capital funds, including Verge HealthTech Fund, Tilia Impact Ventures, PurposeTech, and Estonian angel investors.
The funding will be used to accelerate the rollout of Lifeyear's digital cardiac care platform across selected UK hospitals, GP practices, and virtual wards, enabling the team to refine the technology and validate its clinical potential. The key priorities include generating robust real-world evidence and ensuring compliance with NHS standards, including Digital Technology Assessment Criteria. This will prepare the platform for widespread adoption within the UK healthcare system.
Looking ahead, the Lifeyear team plans to conduct clinical pilots this year at Oxford University Hospitals and in collaboration with the Cardiomyopathy UK charity. They are also actively pursuing UK grant funding and commencing a seed round to support accelerated growth.
Siim Saare, Founder and CEO of Lifeyear, explained the importance of the funding: "This funding is a pivotal step in our mission to reduce the global cardiovascular disease burden. With a stellar team and strategic backing from leading investors and clinical excellence centers, we're focused on redefining how cardiovascular care is delivered, starting with patients who need it the most."
Carl Nicholas Ng, General Partner at Verge HealthTech Fund and lead investor for the round, added: "Lifeyear's combination of clinical rigor and scalable technology makes it stand out. As a fund investing in impactful health tech startups globally, we're excited to back a team poised to shape digital cardiovascular care."
For more information, visit Health Tech World.